Barriers to the Use of Insulin Therapy and Potential Solutions: A Narrative Review of Perspectives from the Asia-Pacific Region

• Main Authors: Chen, Roger, Aamir, Azizul Hasan, Feroz Amin, Mohammod, Bunnag, Pongamorn, Chan, Siew Pheng, Guo, Lixin, Khamseh, Mohammad E., Mohan, Viswanathan, Nicodemus Jr, Nemencio, Roberts, Anthony, Tarigan, Tri Juli Edi, Won, Kyu-Chang, Mehta, Roopa
• Format: Article
• Published: Springer Heidelberg 2024
• Subjects: R Medicine
• Online Access: http://eprints.um.edu.my/45306/; https://doi.org/10.1007/s13300-024-01568-9
• Institution: Universiti Malaya

The rising prevalence of type 2 diabetes (T2D) is posing major challenges for the healthcare systems of many countries, particularly in the Asia-Pacific Region, in which T2D can present at younger ages and lower body mass index when compared with Western nations. There is an important role for insulin therapy in the management of T2D in these nations, but available evidence suggests that insulin is under-utilized and often delayed, to the detriment of patient prognosis. The authors of this article gathered as an advisory panel (representative of some of the larger Asia-Pacific nations) to identify their local barriers to insulin use in T2D, and to discuss ways in which to address these barriers, with their outputs summarized herein. Many of the key barriers identified are well-documented issues of global significance, including a lack of healthcare resources or of an integrated structure, insufficient patient education, and patient misconceptions about insulin therapy. Barriers identified as more innate to Asian countries included local inabilities of patients to afford or gain access to insulin therapy, a tendency for some patients to be more influenced by social media and local traditions than by the medical profession, and a willingness to switch care providers and seek alternative therapies. Strategies to address some of these barriers are provided, with hypothetical illustrative case histories.